KIRA L PRZYBYLKO M.D.
Prescription History 1962474841
Obstetrics & Gynecology in Lawrenceville, NJ


Quality Rating: 95.77 out of 100 score

NPI Status: Active since February 03, 2006

Contact Information

123 FRANKLIN CORNER RD
SUITE 124
LAWRENCEVILLE, NJ
ZIP 08648
Phone: (609) 896-1400
Fax: (609) 896-3986

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for KIRA L PRZYBYLKO M.D., an active Obstetrics & Gynecology specialist practicing in Lawrenceville, NJ. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 156 documented patient claims. Among these therapy options, the most frequently utilized medication is Estradiol, which accounts for 51 claims alone.

Medication Index

No matching medications currently found on file.

Estradiol

Generic Formulation: EstradiolSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 51
30-Day Fills 134.5
Days Supply 4,003
NJ State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills95.6
Peer Average Days Supply2,848
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 27.5% more claims than the standard regional baseline profile for NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,703.37 across this reporting matrix range.

Provider Avg Cost Per Claim

$72.62

State Avg Cost Per Claim

$121.82

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Estring

Generic Formulation: EstradiolSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 17
30-Day Fills 50.2
Days Supply 1,506
NJ State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills58.3
Peer Average Days Supply1,748
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,604.42 across this reporting matrix range.

Provider Avg Cost Per Claim

$506.14

State Avg Cost Per Claim

$519.88

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Premarin

Generic Formulation: Estrogens, ConjugatedSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 23
30-Day Fills 65.0
Days Supply 1,950
NJ State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills47.9
Peer Average Days Supply1,419
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $11,405.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$495.90

State Avg Cost Per Claim

$429.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation containing a mixture of water-soluble, conjugated estrogens derived wholly or in part from URINE of pregnant mares or synthetically from ESTRONE and EQUILIN. It contains a sodium-salt mixture of estrone sulfate (52-62%) and equilin sulfate (22-30%) with a total of the two between 80-88%. Other concomitant conjugates include 17-alpha-dihydroequilin, 17-alpha-estradiol, and 17-beta-dihydroequilin. The potency of the preparation is expressed in terms of an equivalent quantity of sodium estrone sulfate.

Therapeutic Applications

This medication is a female hormone. It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment. Certain estrogen products may also be used by men and women to treat cancers (certain types of prostate cancer, breast cancer that has spread to other parts of the body) and by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure).

Progesterone

Generic Formulation: Progesterone, MicronizedSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 13
30-Day Fills 39.0
Days Supply 1,170
NJ State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills83.1
Peer Average Days Supply2,485
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 60.6% less volume than the regional standard for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $537.71 across this reporting matrix range.

Provider Avg Cost Per Claim

$41.36

State Avg Cost Per Claim

$86.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat infertility in women who do not make enough of a certain natural hormone called progesterone. This hormone is needed to maintain pregnancy. This medication is also used to restore menstrual cycles in women whose cycles have stopped. Progesterone is needed to keep menstrual periods regular.

Raloxifene Hcl

Generic Formulation: Raloxifene HclSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 26
30-Day Fills 75.7
Days Supply 2,270
NJ State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills53.1
Peer Average Days Supply1,578
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,600.57 across this reporting matrix range.

Provider Avg Cost Per Claim

$61.56

State Avg Cost Per Claim

$108.65

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.

Therapeutic Applications

Raloxifene is used by women to prevent and treat bone loss (osteoporosis) after menopause. It slows down bone loss and helps to keep bones strong, making them less likely to break. Raloxifene may also lower the chance of getting a certain type of breast cancer (invasive breast cancer) after menopause. Raloxifene is not an estrogen hormone, but it acts like estrogen in some parts of the body, like your bones. In other parts of the body (uterus and breasts), raloxifene acts like an estrogen blocker. It does not relieve menopause symptoms such as hot flashes. Raloxifene belongs to a class of drugs known as selective estrogen receptor modulators-SERMs. This medication should not be used before menopause. It should not be used to prevent heart disease.

Risedronate Sodium

Generic Formulation: Risedronate SodiumSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 26
30-Day Fills 58.7
Days Supply 1,760
NJ State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills52.3
Peer Average Days Supply1,561
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,530.59 across this reporting matrix range.

Provider Avg Cost Per Claim

$97.33

State Avg Cost Per Claim

$153.31

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.

Therapeutic Applications

Risedronate is used to prevent and treat certain types of bone loss (osteoporosis) in adults. Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases as you age, after menopause, or if you are taking corticosteroid medications (such as prednisone) for a long time. This medication works by slowing bone loss to help maintain strong bones and reduce the risk of broken bones (fractures). Risedronate belongs to a class of medications called bisphosphonates.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like KIRA L PRZYBYLKO M.D. provides transparency into local medical care patterns within Lawrenceville, NJ.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Obstetrics & Gynecology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.